{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:49:44Z","timestamp":1790952584743,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation for Young Scientists of China","award":["81802863"],"award-info":[{"award-number":["81802863"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773008"],"award-info":[{"award-number":["81773008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972897"],"award-info":[{"award-number":["81972897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018030310285"],"award-info":[{"award-number":["2018030310285"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education","award":["LC2019ZD003"],"award-info":[{"award-number":["LC2019ZD003"]}]},{"name":"Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University","award":["2020J011"],"award-info":[{"award-number":["2020J011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Organ-specific metastatic context has not been incorporated into the clinical practice of guiding programmed death-(ligand) 1 [PD-(L)1] blockade, due to a lack of understanding of its predictive versus prognostic value. We aim at delineating and then incorporating both the predictive and prognostic effects of the metastatic-organ landscape to dissect PD-(L)1 blockade efficacy in non-small cell lung cancer (NSCLC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 2062 NSCLC patients from a double-arm randomized trial (OAK), two immunotherapy trials (FIR, BIRCH), and a real-world cohort (NFyy) were included. The metastatic organs were stratified into two categories based on their treatment-dependent predictive significance versus treatment-independent prognosis. A metastasis-based scoring system (METscore) was developed and validated for guiding PD-(L)1 blockade in clinical trials and real-world practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients harboring various organ-specific metastases presented significantly different responses to immunotherapy, and those with brain and adrenal gland metastases survived longer than others [overall survival (OS), <jats:italic>p<\/jats:italic> = 0.0105; progression-free survival (PFS), <jats:italic>p<\/jats:italic> = 0.0167]. In contrast, survival outcomes were similar in chemotherapy-treated patients regardless of metastatic sites (OS, <jats:italic>p<\/jats:italic> = 0.3742; PFS, <jats:italic>p<\/jats:italic> = 0.8242). Intriguingly, the immunotherapeutic predictive significance of the metastatic-organ landscape was specifically presented in PD-L1-positive populations (PD-L1 &gt; 1%). Among them, a paradoxical coexistence of a favorable predictive effect coupled with an unfavorable prognostic effect was observed in metastases to adrenal glands, brain, and liver (category I organs), whereas metastases to bone, pleura, pleural effusion, and mediastinum yielded consistent unfavorable predictive and prognostic effects (category II organs). METscore was capable of integrating both predictive and prognostic effects of the entire landscape and dissected OS outcome of NSCLC patients received PD-(L)1 blockade (<jats:italic>p<\/jats:italic> &lt; 0.0001) but not chemotherapy (<jats:italic>p<\/jats:italic> = 0.0805) in the OAK training cohort. Meanwhile, general performance of METscore was first validated in FIR (<jats:italic>p<\/jats:italic> = 0.0350) and BIRCH (<jats:italic>p<\/jats:italic> &lt; 0.0001), and then in the real-world NFyy cohort (<jats:italic>p<\/jats:italic> = 0.0181). Notably, METscore was also applicable to patients received PD-(L)1 blockade as first-line treatment both in the clinical trials (OS, <jats:italic>p<\/jats:italic> = 0.0087; PFS, <jats:italic>p<\/jats:italic> = 0.0290) and in the real-world practice (OS, <jats:italic>p<\/jats:italic> = 0.0182; PFS, <jats:italic>p<\/jats:italic> = 0.0045).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Organ-specific metastatic landscape served as a potential predictor of immunotherapy, and METscore might enable noninvasive forecast of PD-(L)1 blockade efficacy using baseline radiologic assessments in advanced NSCLC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02315-2","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T01:02:41Z","timestamp":1649725361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice"],"prefix":"10.1186","volume":"20","author":[{"given":"Si-Cong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Shan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Le","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. John","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Xin","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Qin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-0060","authenticated-orcid":false,"given":"Zhong-Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"issue":"24","key":"2315_CR1","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"issue":"328","key":"2315_CR2","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2315_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/2159-8290.Cd-17-1320","volume":"8","author":"W Pao","year":"2018","unstructured":"Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, et al. Tissue-specific immunoregulation: a call for better understanding of the \u201cimmunostat\u201d in the context of cancer. Cancer Discov. 2018;8(4):395\u2013402. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1320.","journal-title":"Cancer Discov"},{"issue":"1","key":"2315_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011.","journal-title":"Immunity."},{"issue":"2","key":"2315_CR5","doi-asserted-by":"publisher","first-page":"e0192227","DOI":"10.1371\/journal.pone.0192227","volume":"13","author":"M Tamiya","year":"2018","unstructured":"Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, et al. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One. 2018;13(2):e0192227. https:\/\/doi.org\/10.1371\/journal.pone.0192227.","journal-title":"PLoS One"},{"issue":"5","key":"2315_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","volume":"17","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhu L, Guo T, Chen W, Zhang Z, Li W, et al. Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother. 2021;17(5):1278\u201387. https:\/\/doi.org\/10.1080\/21645515.2020.1823779.","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"2315_CR7","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/jco.2015.63.3651","volume":"33","author":"KV Ballman","year":"2015","unstructured":"Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33(33):3968\u201371. https:\/\/doi.org\/10.1200\/jco.2015.63.3651.","journal-title":"J Clin Oncol"},{"key":"2315_CR8","unstructured":"A Phase III, Open-Label, Multicenter, Randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with docetaxel in patients with non-small cell lung cancer after failure with platinum containing chemotherapy (OAK). Vivli 10.25934\/00005794 (2017)."},{"key":"2315_CR9","unstructured":"A Phase II, Multicenter, single-arm study of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Vivli 10.25934\/00005791 (2018)."},{"key":"2315_CR10","unstructured":"A Phase II, Multicenter, single-arm study of atezolizumab in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (BIRCH). Vivli 10.25934\/00005796 (2017)."},{"issue":"10066","key":"2315_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x.","journal-title":"Lancet."},{"issue":"9","key":"2315_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0134-3.","journal-title":"Nat Med"},{"issue":"11","key":"2315_CR13","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","volume":"13","author":"DR Spigel","year":"2018","unstructured":"Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC. J Thorac Oncol. 2018;13(11):1733\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.004.","journal-title":"J Thorac Oncol"},{"issue":"24","key":"2315_CR14","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/jco.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters S, Gettinger S, Johnson ML, J\u00e4nne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781\u20139. https:\/\/doi.org\/10.1200\/jco.2016.71.9476.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2315_CR15","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1158\/1078-0432.Ccr-19-2968","volume":"26","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Garrett-Mayer E, Karapetis CS, Rowland A, Sorich MJ. Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab. Clin Cancer Res. 2020;26(13):3280\u20136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2968.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2315_CR16","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/jco.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457\u201365. https:\/\/doi.org\/10.1200\/jco.2011.34.7625.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2315_CR17","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","volume":"17","author":"DS Ettinger","year":"2019","unstructured":"Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Cancer Netw. 2019;17(12):1464\u201372. https:\/\/doi.org\/10.6004\/jnccn.2019.0059.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"36","key":"2315_CR18","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/jco.19.00709","volume":"37","author":"JC Osorio","year":"2019","unstructured":"Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, et al. Lesion-level response dynamics to programmed cell death protein (PD-1) blockade. J Clin Oncol. 2019;37(36):3546\u201355. https:\/\/doi.org\/10.1200\/jco.19.00709.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2315_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00262-019-02462-1","volume":"69","author":"G Zhang","year":"2020","unstructured":"Zhang G, Cheng R, Wang H, Zhang Y, Yan X, Li P, et al. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Cancer Immunol Immunother. 2020;69(3):399\u2013405. https:\/\/doi.org\/10.1007\/s00262-019-02462-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2315_CR20","doi-asserted-by":"publisher","first-page":"1909296","DOI":"10.1080\/2162402x.2021.1909296","volume":"10","author":"SC Ma","year":"2021","unstructured":"Ma SC, Tang XR, Long LL, Bai X, Zhou JG, Duan ZJ, et al. Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology. 2021;10(1):1909296. https:\/\/doi.org\/10.1080\/2162402x.2021.1909296.","journal-title":"Oncoimmunology."},{"key":"2315_CR21","doi-asserted-by":"publisher","first-page":"102893","DOI":"10.1016\/j.critrevonc.2020.102893","volume":"147","author":"BD Qin","year":"2020","unstructured":"Qin BD, Jiao XD, Liu J, Liu K, He X, Wu Y, et al. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Crit Rev Oncol Hematol. 2020;147:102893. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102893.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2315_CR22","doi-asserted-by":"publisher","first-page":"1746113","DOI":"10.1080\/2162402x.2020.1746113","volume":"9","author":"S Li","year":"2020","unstructured":"Li S, Sun S, Xiang H, Yang J, Peng M, Gao Q. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. Oncoimmunology. 2020;9(1):1746113. https:\/\/doi.org\/10.1080\/2162402x.2020.1746113.","journal-title":"Oncoimmunology."},{"key":"2315_CR23","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/cmar.S310331","volume":"13","author":"WJ Yin","year":"2021","unstructured":"Yin WJ, Ma SC, Dong ZY, Xu M, Mao W. Efficacy and treatment strategies in advanced cancers with liver metastasis receiving atezolizumab therapy. Cancer Manag Res. 2021;13:4541\u201351. https:\/\/doi.org\/10.2147\/cmar.S310331.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2315_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","volume":"80","author":"MS van der Heijden","year":"2021","unstructured":"van der Heijden MS, Loriot Y, Dur\u00e1n I, Ravaud A, Retz M, Vogelzang NJ, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial. Eur Urol. 2021;80(1):7\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.024.","journal-title":"Eur Urol"},{"key":"2315_CR25","unstructured":"A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) Compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy. Vivli 10.25934\/00005598 (2018)."},{"issue":"10064","key":"2315_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376. https:\/\/doi.org\/10.1016\/s0140-6736(16)32455-2.","journal-title":"Lancet."},{"issue":"7693","key":"2315_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature."},{"key":"2315_CR28","unstructured":"A phase II, multicenter, single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer. Vivli. 10.25934\/00005804 (2017)."},{"issue":"21","key":"2315_CR29","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020.","journal-title":"Cell."},{"key":"2315_CR30","doi-asserted-by":"publisher","unstructured":"Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2021. https:\/\/doi.org\/10.1016\/j.jtho.2021.09.014.","DOI":"10.1016\/j.jtho.2021.09.014"},{"issue":"5","key":"2315_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387\u2013401. https:\/\/doi.org\/10.1016\/s2213-2600(19)30084-0.","journal-title":"Lancet Respir Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02315-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T01:03:28Z","timestamp":1649725408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02315-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02315-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"4 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethical Review Boards of Nanfang Hospital. All patients enrolled in OAK, FIR, and BIRCH provided signed informed consent in accordance with the protocols of the corresponding studies. Deidentified individual-participant data of the three clinical trials were accessed according to Roche\u2019s policy and process for clinical study data sharing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no actual or potential conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}